N@N

STOCKHOLM--([ BUSINESS WIRE ])--Regulatory News:

"This positive news from EFS confirms our strong position in the market for transplantation diagnostics. The choice of our SSP products for HLA typing to all EFS member transplantation laboratories is also recognition of our French partner BioNoBis and the result of strong local presence"

The French blood center organization EFS has in thistender chosen HLA typing products from Allenex (STO:ALNX). After a central evaluation, it is clear that the 17 transplant laboratories that are part of EFS during the next four years will use typing products from Allenex subsidiary Olerup SSP.

This is the first time that SSP typing products are acquired on a national level purchasing agreement on the to Allenex important French market. This contract has therefore been followed with interest on the global transplantation market. Allenex and its French partner BioNoBis ensures major new sales volumes at the same time that existing business is secured.

"We are pleased that the solution for HLA typing, which we offered EFS has won us the contract" says Pascal Herve, President of BioNoBis and responsible for the negotiations. "The products from Allenex/Olerup SSP, along with our technical expertise and strong local customer support have proven to be a winning suggestion to EFSa he continues.

The expected value of purchases for Allenex is about 6 MSEK per year for four years, a total of about 24 MSEK. The net direct sales increase is about 3 MSEK per year, but a negative outcome of the negotiation would have meant a sales decrease by a corresponding amount. The transaction is handled locally by Allenex French partner BioNoBis. They have been the partner of Allenex/Olerup SSP in France for many years and they have a strong position in the market for transplantation diagnostics.

"This positive news from EFS confirms our strong position in the market for transplantation diagnostics. The choice of our SSP products for HLA typing to all EFS member transplantation laboratories is also recognition of our French partner BioNoBis and the result of strong local presence" says Anders Karlsson, CEO of Allenex.

Allenex AB discloses the information provided herein pursuant to the Securities Markets ActAnd/or the Financial Instruments Trading Act. The information was submitted for publication on Sep 27, 2012, at 08.45 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 52 persons are employed in the Allenex group.

This information was brought to you by Cision [ http://www.cisionwire.com ]